Compare CCBG & OMER Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CCBG | OMER |
|---|---|---|
| Founded | 1895 | 1994 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 874.1M | 844.6M |
| IPO Year | 1994 | 2008 |
| Metric | CCBG | OMER |
|---|---|---|
| Price | $51.52 | $18.96 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | ★ $50.00 | $32.50 |
| AVG Volume (30 Days) | 48.1K | ★ 2.2M |
| Earning Date | 04-20-2026 | 05-14-2026 |
| Dividend Yield | ★ 2.34% | N/A |
| EPS Growth | 15.38 | ★ 98.15 |
| EPS | ★ 0.92 | 0.77 |
| Revenue | N/A | ★ $29,868,000.00 |
| Revenue This Year | $6.25 | N/A |
| Revenue Next Year | $3.17 | $233.22 |
| P/E Ratio | $56.05 | ★ $24.61 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $38.27 | $3.94 |
| 52 Week High | $53.60 | $19.65 |
| Indicator | CCBG | OMER |
|---|---|---|
| Relative Strength Index (RSI) | 53.30 | 71.49 |
| Support Level | $50.98 | $18.00 |
| Resistance Level | $52.10 | $19.65 |
| Average True Range (ATR) | 0.98 | 0.88 |
| MACD | -0.13 | -0.14 |
| Stochastic Oscillator | 54.14 | 75.10 |
Capital City Bank Group Inc is a United States-based group engaged in Banking services, Trust and asset management services, and Brokerage services. The company operates in one segment with two principal services: Banking Services and Wealth Management Services. It offers retail and commercial banking business in the form of traditional deposit and credit services, asset management, trust, mortgage banking, merchant services, bank cards, data processing, and securities brokerage services, among others, through its banking offices in Florida, Georgia, and Alabama.
Omeros Corp is an inventive, commercial-stage biotechnology company that discovers and develops first-in-class protein and small-molecule therapeutics for large-market and orphan indications, with particular emphasis on complement-mediated diseases, cancers, and addictive or compulsive disorders. The company's clinical-stage development programs include: narsoplimab, its antibody targeting mannan-binding lectin-associated serine protease 2 (MASP-2), the effector enzyme of the lectin pathway of complement; OMS1029, its long-acting antibody targeting MASP-2; and OMS527, its phosphodiesterase 7 (PDE7) inhibitor program.